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Abstract
Retroviruses consist of a varied family of enveloped RNA viruses with positive-sense
RNAs that replicate in a host cell through the process of reverse transcription. Retrovirus‐
es belong to the Retroviridae family that typically carries their genetic material in the
form of ribonucleic acid, while the genetic material of their hosts is in the form of deoxy‐
ribonucleic acid. Infections with a number of retroviruses can lead to serious conditions,
such as AIDS, a range of malignancies, neurological diseases, and added clinical condi‐
tions. In addition, some can even become integrated as DNA in the germ line and passed
as endogenous viruses from generation to generation. Surprisingly, retroviruses do not
appear to straightforwardly activate host innate defenses. On the other hand, attention in
these viruses extends beyond their disease causing capabilities. For example, studies on
the retroviruses led to the discovery of oncogenes, understanding of mechanisms that
regulate eukaryotic gene expression, and these are proving to be valuable research tools
in molecular biology and have been used successfully in gene therapy. The central goals
of retrovirology today are the treatment and the prevention of human and non-human
diseases and to use this virus in research.
Keywords: retrovirus, Retroviridae, reverse transcriptase, replication, immune responses,
ART
1. Introduction
During the past few decades retrovirus has done an adequate amount of harm to the human
life and became a big threat globally. These are the group of viruses that belong to the family
Retroviridae and that typically carry their genetic material in the form of ribonucleic acid
(RNA), while the genetic material of their hosts is in the form of deoxyribonucleic acid (DNA).
Retroviruses are named for an enzyme known as reverse transcriptase (RT), which was
discovered independently in 1971 by American virologists Howard Temin and David
Baltimore for which they have received Nobel Prize in physiology and medicine in the year
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1975. Retroviridae is a family of enveloped, obligate parasites with single-stranded positive-
sense RNA (ssRNA) that replicate in a host cell through the process of reverse transcription.
The activity of RT makes it feasible for genetic material from a retrovirus to become perma‐
nently integrated into the DNA genome (provirus) of an infected cell.
Figure 1. Classification of Retroviridae family of viruses.
Retroviridae is subdivided into Orthoretrovirinae and Spumaretrovirinae (Figure 1). Under
Orthoretrovirinae the various genus are Alpharetrovirus (Rous sarcoma virus, avian sarcoma
leukosis virus), Betaretrovirus (Mouse mammary tumor virus, Jaagsiekte sheep retrovirus),
Gammaretrovirus (murine leukemia virus, Abelson murine leukemia virus, Friend virus, koala
retrovirus, xenotropic murine leukemia-related virus), Deltaretrovirus (Human T-lymphotrop‐
ic virus (HTLV) types 1–4, simian T-lymphotropic virus types 1–4, Bovine leukemia virus),
Epsilonretrovirus (Walleye epidermal hyperplasia virus), and Lentivirus (human immunodefi‐
ciency virus (HIV), simian immunodeficiency viruses (SIV), feline immunodeficiency virus,
puma lentiviruses, bovine immunodeficiency virus, caprine arthritis encephalitis virus, visna
virus) are present, whereas under Spumaretrovirinae only one genus is present spumavirus
(simian foamy virus, human foamy virus) [1]. The retroviruses host range include human,
murine, feline (cat), avian (birds), and bovine (pig), and it is dependent upon the viral envelope,
glycoproteins and structural proteins, involved in integration. Infections with a number of
retroviruses can lead to serious conditions, such as AIDS, a range of malignancies, neurological
diseases, and added clinical conditions [2]. In addition, some retroviruses can even become
integrated as DNA in the germ line and passed as endogenous viruses from generation to
generation. Using retrovirus in research has built up the need to advance the investigation in
detail regarding the viral particles and genomes, their modes of replication, integration, and
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host immune evasion. The basic replication of retroviruses includes that (Figure 2) the ssRNA
become double-stranded DNA (dsDNA) and gets into the host genetic material and employs
host machinery for the synthesis of new virions.
Figure 2. The reverse of Cricks’ central dogma that occurs in retroviruses. RNA genome is converted by reverse tran‐
scriptase into double-stranded DNA, followed by integration into the host genome, transcription and translation of vi‐
ral proteins occurs along with the host.
Interesting Points about Retroviruses 
 Retroviruses contain RNA as genetic material but have DNA-dependent steps in 
their replication. 
 Replicates via reverse transcription because of the presence of reverse transcriptase 
enzyme. 
 Integrase transfers the viral DNA into the cell nucleus and viral dsDNA is 
covalently and randomly integrated into the cell’s genome. 
 Retroviruses that can transform host cells at high rates contain gene sequences such 
as viral oncogenes and proto-oncogenes. 
 Human retroviruses can cause immune deficiencies, cancer, and neurological 
diseases. 
Molecular Biology and Pathogenesis of Retroviruses
http://dx.doi.org/10.5772/62885
5
2. Retrovirus structure, genome, and proteins
The typical retrovirus structure is enveloped, spherical to pleomorphic in shape, and they have
diameter of 80–100 nm. The different genuses of retrovirus virions (Figure 3) have diverse
morphology, but they have their same virion component, which includes the outer envelope
coat, two copies of the genetic material, and the viral proteins. Envelope consists of lipids that
are obtained from the host plasma membrane during budding process and the glycoprotein
such as gp120 and gp41 in case of HIV [3]. The retroviral envelope serves three separate
functions that includes the outer lipid bilayer protects from the extracellular environment, it
also aids in the entry and way out of host cells through endosomal membrane trafficking, and
the facility to straightforwardly enter cells by fusing with their membranes.
Figure 3. Schematic cross section through a retroviral particle: Showing retrovirus components.
The genome of retrovirus is monopartite, linear, dimeric, ssRNA (+) of about 8–10 kb, with a
5’-cap and a 3’poly-A tail (Figure 4). The group-specific gene (gag), pol, pro, envelope (env)
genes are flanked between the R regions. The 5’-long terminal repeats (LTRs) consist of U3
(unique sequence), R primer binding site (PBS), and U5 regions. The 3’ end consists of a
polypurine tract (PPT), U3, and R regions. The R region is a short repeated sequence at each
end of the genome used during the reverse transcription to ensure correct end-to-end transfer
in the growing chain. U5, on the other hand, is a short exceptional arrangement in the middle
of R and PBS [4]. PBS consists of 18 bases corresponding to 3’ end of tRNA primer. L region is
an untranslated leader region that gives the sign for packaging of the genome RNA. The
retroviral protein includes gag, protease, pol, and env proteins. Gag is the primary retroviral
structural protein responsible for orchestrating the majority of steps in viral assembly. Most
of these assembly steps occur through interactions with three gag subdomains—matrix (MA),
capsid (CA), and nucleocapsid (NC). The gag subdomains are structurally discrete but have
functionally overlapping roles in the viral assembly process [5, 6].
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Figure 4. Retrovirus structure and genome: The three significant protein coding genes include group-specific gene
(gag), pol, envelope (env) genes, which are flanked between the R regions and codes for capsid, reverse transcriptase,
integrase, protease, and envelope proteins, respectively. Retroviruses are characterized by the 5′ and 3′ long terminal
repeat (LTR) sequences, which are thought to control and gene expression. The LTRs each contain two unique non-
protein-coding sequences, called U5 at the 5′ end and U3 at the 3′ end, which encodes controlling elements. PBS con‐
sists of 18 bases corresponding to 3' end of tRNA primer. The R region is a short repeated sequence at each end of the
genome used during the reverse transcription to ensure correct end-to-end transfer in the growing chain.
3. Genetic variations and retroviruses
Retroviruses, similar to all RNA viruses, show a high mutation rate. The real component for
creating genetic variation within retroviral populations is because of the polymerization error
during DNA synthesis by RT, which does not have a proofreading activity [7]. The reason for
this high genetic variation is because of viral mutation rate, recombination rate, rate of
replication, size of the viral population, and selective forces [8, 9]. Genetic variation has been
documented extensively in populations of HIV type 1. This genetic adaptability has significant
consequences for the evolution of HIV-1 and other retroviruses and their impact on human
health [8]. Because of the genetic variations, retroviruses are expanding its host range; for
example, HIV-1 can switch from using the CCR5 co-receptor to using the CXCR4 co-receptor
[10]. This difference in retroviral populations provides a mechanism for retroviruses to escape
host immune responses and expand resistance to all known antiretroviral drugs [7, 11].
4. Replication of retroviruses
Replication is a multistep process; each step is crucial for the virus entry and multiplies itself
in the host cell. The study of retroviruses particle assembly, budding, and release has been
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especially rich in terms of the exchange of concepts and techniques with related areas of cell
biology [12]. There are seven steps in the replication cycle of the retrovirus (Figure 5). The
initial step is attachment, in which the retrovirus utilizes one of its glycoproteins to attach to
one or more particular cell-surface receptors on the host cell. Some retroviruses likewise utilize
an optional receptor, referred to as the co-receptor. The second and third steps are penetration
and uncoating, individually. Retroviruses infiltrate the host cell by direct fusion of the virion
envelope with the plasma membrane of the host. The fourth step is replication, which happens
after the retrovirus undergoes partial uncoating thereby releasing its genome and three
essential enzymes (RT, integrase, and pol gene coding enzymes). At this stage, the RNA
genome is converted by RT into double-stranded DNA, followed by integration into the host
genome, transcription and translation of viral proteins along with the host. The fifth step is
assembly, in which retrovirus capsids are assembled in an immature form. The sixth step is
budding, in which the immature viral particle acquires the host plasma membrane, and the
final step is maturation and release, in which the gag and pol proteins of the retrovirus are
cleaved by the retroviral protease, thus forming the mature and infectious form of the virus
[13]. The retrovirus replication is well studied in case of HIV virus. HIV replicates million of
time per day, destroying the host immune cells and eventually causing disease progression.
During HIV replication the virus recognizes host cell such as CD4+ T- lymphocyte. Entry of
HIV into the cells requires certain substances on the cell surface such as CD4 receptor and co-
receptors such as CCR5 and CXCR4 [14]. These receptors interact with protein complexes that
are embedded in the viral envelope. The viral proteins consist of extracellular gp120 and trans-
membrane gp41 proteins. When HIV approaches the target cell, the gp120 binds with the cell
surface receptor, this process is termed as attachment. Following co-receptor binding results
in a conformational change in gp120, this allows gp41 to unfold and extend its hydrophobic
terminal into the cell membrane. gp41 then folds back on itself, this causes the virus to move
close toward the cell and facilitates the fusion of their membranes. The viral nucleocapsid then
enters the cell and releasing two viral RNA strands and three essential replication enzymes;
integrase, protease, and RT. HIV RT is a heterodimer composed of two subunits (p66 and p51).
At first, RT begins the reverse transcription of viral RNA; it consists of two catalytic domains
—ribonuclease H active site and polymerase active site. In the polymerase active site, single-
stranded viral RNA is transcribed into an RNA-DNA double helix. These RNA-DNA hybrids
are cleaved into individual stands by ribonuclease H. The polymerase then completes the
remaining strand into DNA double helix (dsDNA). After the formation of dsDNA, integrase
moves into action, it cleaves each dinucleotide from 3’ end of the DNA creating two sticky
ends. Integrase then transfers the viral DNA into the cell nucleus and viral dsDNA is covalently
and randomly integrated into the cell’s genome [15]. The host cell genome now contains the
genetic information of HIV virus. Activation of the host cell induces the transcription of
proviral DNA by Pol II produces viral spliced and unspliced messenger RNAs. This messenger
RNA now migrates into the cytoplasm, where building blocks for a new virus were synthe‐
sized. Some of the building blocks have to be processed by the viral protease where longer
proteins are cleaved into small core proteins. The processing of viral proteins is crucial to create
an infectious virus. Translation of unspliced viral RNAs produces env, gag, and gag-pol
polyproteins. The two viral RNA strands with three enzymes come together and core proteins
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assemble around them forming a capsid, which is an immature virus particle. Capsid leaves
the host cell by acquiring new envelope of host and viral proteins (mature virus) such as gp120
and gp41; this process is known as budding. Recent reports suggest that during this process
of budding, clathrin is recruited into the HIV particle with high specificity [16]. These matured
virus become ready to infect the other cells [15]. A critical aspect of viral replication is the
assembly of virus particles, which are subsequently released as progeny virus. While a great
deal of attention has been focused on better understanding this phase of the viral lifecycle,
many aspects of the molecular details remain poorly understood.
Figure 5. Replication of retroviruses: There are seven steps in the replication cycle of the retrovirus. The initial step is
attachment, in which the retrovirus utilizes one of its glycoproteins to attach to one or more particular cell-surface re‐
ceptors on the host cell. Some retroviruses likewise utilize an optional receptor, referred to as the co-receptor. The sec‐
ond step is penetration and uncoating, individually. Retroviruses infiltrate the host cell by direct fusion of the virion
envelope with the plasma membrane of the host. The third step is replication, which happens after the retrovirus un‐
dergoes partial uncoating thereby releasing its genome and three essential enzymes. At this stage, the RNA genome is
converted by reverse transcriptase into double-stranded DNA (dsDNA). The fourth step is integration, in which retro‐
virus dsDNA integrates into the host genome followed by transcription and translation of the viral proteins occurs.
The fifth step includes proteolytic processing of viral proteins. The sixth step includes assembly of viral proteins and
RNA. The seventh step is budding, in which the immature viral particle acquires the host plasma membrane and final
step is maturation and release, in which the gag and pol proteins of the retrovirus are cleaved by the retroviral pro‐
tease, thus forming the mature and infectious form of the virus.
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A provirus can be transmitted through the germ line from parents to offspring as an endoge‐
nous retrovirus [17, 18]. Human endogenous retroviruses (HERVs) account for about 8% of
the human genome [19]. Exogenous retroviruses seem to have arisen from endogenous
retrotransposons by acquisition of a cellular envelope gene [20]. The existence of HERVs has
been identified for many years, but their abundance in the genome was not predicted by earlier
studies [21]. Retroviral genome gets into human genome and by de novo insertion followed
by activation of downstream proto-oncogenes, or by gene disruption [22]. Retrovirus integra‐
tion does not occur in resting (Go phase) cells yet rather requires that cells be in the S phase
(DNA synthesis) of their mitotic cycle. Since the mitotic phase is induced by a binary recog‐
nition event, integration and virus reproduction perhaps require that the invaded target T-cell
interact with the appropriate B-cell-processed antigen complex. Once the viral cDNA integra‐
tes, transcription to mRNA proceeds at some rate that depends on the details of the infecting
virus and the invaded cell [23]. It is also reported that enhancer and promoter elements in
retroviral LTRs can influence the transcription of next genes that can result in transcriptional
activation or gene silencing and which may result in abnormal expression of tissue-specific
proteins [24]. The human genome contains many endogenous retroviral sequences, and these
have been suggested to play important roles in a number of physiological and pathological
processes. Researchers also found that ERVs also take part in the body’s immune defense
against regular bacterial and viral pathogens. HERVs are classified into three broad classes (I,
II, III). Analysis of the draft human genome has so far found only three HERV proviruses with
complete open reading frames for gag, pol, and env, which are considered as essential viral
genes, and at least one of these HERVs is mutated at a critical residue in the reverse transcrip‐
tase domain of pol [25]. HERVs have frequently been reported as etiological cofactors in
chronic diseases such as cancer, autoimmunity, and neurological disease.
5. Mode of transmission
Most of the retroviruses transmission occurs through cell to cell, mother to fetus transmission,
and through biological fluids. Cell-to-cell transmission of retroviruses is much more efficient
as compared with cell-free conditions, and as retroviruses reach through the tight cell-cell
interface, they are out of reach of the immune system [26]. Retrovirus employs various
mechanisms of immune evasion, however, and can destroy the immune system or subvert it
to enable successful transmission [27].
6. Immune system and retroviruses
The human immune system needs to manage with various pathogens, ranging from RNA
viruses to 30-foot-long tapeworms [28]. Although we have gained much understanding of
innate immune recognition of many microbial pathogens, currently we have very little
knowledge about innate immune responses against retroviral infections [29]. The immune
system retroviruses (ISRV) are defined as a retrovirus (HIV) whose target is T4-positive T-
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helper cells of the immune system that requires stimulation by antigens to reproduce. T-cells
are part of the response mechanism that defends the body against attacking agents and are
stimulated to reproduce by such agents [23]. Antiviral responses are characteristically marked
by stimulation of type I interferon through various mechanisms that recognize viral nucleic
acids. These responses restrain the viral replication by various mechanisms and activate the
adaptive immune responses with the help of antigen presenting cells and also aids in devel‐
oping memory and viral clearance. But, quite number of reports suggests that viruses also have
developed a variety of means for circumventing innate immune responses, ensuring their
survival and transmission. Surprisingly retroviruses do not appear to straightforwardly
activate host innate defenses. It was observed that generalized immune activation and
increased amount of cytokines and immunoglobulins along with the progressive loss of CD4+
T-cells was reported during HIV-1 infection [30].
Generally, viral infection triggers innate immune sensors to produce type I interferon.
However, this is not the case with retroviruses; the reason is still not known. The recent reports
suggest various molecules it includes: TREX1, which is a cytosolic exonuclease that degrades
DNA [31] derived from HIV or endogenous retroelements, thereby preventing the accumula‐
tion of cytosolic DNA, which would otherwise trigger innate immunity. In a study on Trex1(-/-)
mouse cells and human CD4(+) T-cells and macrophages in which TREX1 was inhibited by
RNA-mediated interference, cytosolic HIV-DNA accumulated and HIV infection induced type
I interferon that inhibited HIV replication and spreading [32]. The recent study on innate
immune sensors during retroviral infection has identified the enzyme cyclic guanosine
monophosphate–adenosine monophosphate (cGAMP) synthase (cGAS) which triggers the
cytosolic DNA and activates the production of type I interferons and other cytokines. The
mechanism in which these sensors act by includes firstly viral DNA binds and activates cGAS,
which catalyzes the synthesis of a cGAMP isomer from adenosine triphosphate (ATP) and
guanosine triphosphate (GTP). This cGAMP isomer that is termed has 2′3′-cGAMP contains
both 2′-5′ and 3′-5′ phosphodiester linkages. cGAMP then binds and activates the endoplasmic
reticulum protein stimulator of IFN genes (STING) and functions as a second messenger.
STING activates the NF- κB, interferon regulatory factor 3 (IRF3) to induce interferons and
other cytokines through the activation of protein kinases IκB kinase (IKK) and TANK-binding
kinase 1 (TBK1) [32–35]. In our view, there is currently insufficient understanding about how
the retroviral infection, in general, is sensed by the innate immune system. If the innate immune
part is traced, that will aid in understanding the activation of adaptive immunity and devel‐
opment of antiviral against retroviruses.
7. Antiretroviral therapy
There are about 34 million HIV-1–infected people in the world [36], and this number plainly
says that there is an urgent unmet need for investigation of antiretroviral therapy (ART), and
management of this worldwide risk is highly desired [37]. ART is treatment of people infected
with the retroviruses using anti-retroviral drugs. The goal of antiretroviral therapy is to reduce
the amount of virus in infected individual body (viral load) to a level that can no longer be
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detected with ongoing treatment blood test. Considerable advances in ART have been made
since the introduction of zidovudine (3'-azido-3'-deoxythymidine—AZT) in 1987 [38]. The
regular treatment consists of a grouping of at least three drugs called as highly active antire‐
troviral therapy (HAART) that hold back the viral replication within the host cell and thereby
reduces the viral load.
Six classes of antiretroviral agents (Table 1) currently exist (specifically towards HIV); they
include the following:
1. Nucleoside reverse transcriptase inhibitors (NRTIs) such as abacavir, emtricitabine, and
tenofovir [39] takes action by interfering with the HIV replication cycle through compet‐
itive inhibition of reverse transcriptase enzyme a key enzyme in replication and thereby
terminates the DNA formation. These can also terminate the DNA formation by incorpo‐
rating into the proviral DNA; the reason is that NRTIs are structurally similar to the DNA
nucleoside bases.
2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) includes niverapine, efavirenz,
and etravirine, which acts by non-competitive binding of NNRTIs at the hydrophobic
pocket of p66 subunit of the enzyme results in a conformational change and alters the
active site and limits RT activity. The limitation of these drugs is that it has a low genetic
barrier, i.e., a single mutation in RT genome induces a high-level of phenotypic resistance
and prevents its use [40–42].
3. Protease inhibitors (PIs) include indinavir, atazanavir, darunavir, and tipranavir. This
retrovirus protease is a 99-amino-acid, aspartic acid protein, which plays an important
role in the maturation of virus particles late in the viral life cycle. During or immediately
after viral budding from an infected cell, proteases systematically cleaves individual
proteins from the gag and gag-pol polypeptide precursors into functional subunits for
viral capsid formation. Protease inhibitors act as competitive inhibitors that directly bind
to protease and put off the subsequent cleavage of polypeptides. It has recently been
suggested that PIs can directly inhibit lymphocyte apoptosis and this effect may contribute
to an immunologic benefit independently of an antiviral effect [43–45].
4. Integrase inhibitors (INSTIs) such as dolutegravir and raltegravir are used in combination
with a protease inhibitor and target the strand transfer step of retroviral DNA integration.
These are approved by FDA in 2007. Integration is essential for viral replication and is
thus an attractive target for novel chemotherapy [46]. The integrase enzyme is responsible
for transfer of virus-encoded DNA to the host cell chromosome, a necessary event in
retrovirus replication [15] INSTIs active against a wide range, including both CCR5 co-
receptor and CXCR4 coreceptor–using strains [47].
5. Fusion inhibitors (FIs) include enfuvirtide—act extracellularly to prevent the fusion. It is
a peptide based on the gp41 sequence that specifically prevents membrane fusion by
competitively binds to gp41 and preventing the conformational change of gp41 required
to complete the final step in the fusion process [48].
Advances in Molecular Retrovirology12
6. Chemokine receptor antagonist. This small molecule such as maraviroc [49] selectively
and reversibly binds the CCR5 coreceptor, blocking the V3 loop interaction and inhibiting
fusion of the cellular membranes. Using these inhibitors individually or in combination
the virus replication process is slowed and the retroviruses find it more difficult to
overcome this combined attack. ART has the potential both to reduce mortality and
morbidity rates among infected people, and to improve their quality of life [50].
Antiretroviral agents Examples Mode of action
1.
Nucleoside reverse transcriptase
inhibitors (NRTIs) Abacavir, Emtricitabine
Competitive inhibition of reverse
transcriptase enzyme a key enzyme in







Non-competitive binding of NNRTIs at
the hydrophobic pocket of p66 subunit of
the reverse transcriptase enzyme results
in a conformational change and alters the
active site and limits enzyme activity.
3.
Protease inhibitors (PIs) Indinavir, Atazanavir,Darunavir, Tipranavir
Act as competitive inhibitors that directly
bind to protease and put off the
subsequent cleavage of polypeptides
which is an important step in viral
maturation.
4. Integrase inhibitors (INSTIs) Dolutegravir, Raltegravir Target the strand transfer step ofretroviral DNA integration.
5.
Fusion inhibitors (FIs) Enfuvirtide
Specifically prevents membrane fusion by
competitively binding to gp41 and
preventing the conformational change of
gp41 required to complete the final step in
the fusion process.
6.
Chemokine receptor antagonist Maraviroc
It binds selectively and reversibly binds
the CCR5 coreceptor, blocking the V3 loop
interaction and inhibiting fusion of the
cellular membranes.
Table 1. Classes of antiretroviral agents and their mode of action
8. Conclusions
The central goals of retrovirology nowadays are the treatment and the prevention of human
and non-human diseases and to use this virus in research. Recent studies have shown that
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retroviruses can be used in a number of ways such as model for biological research, for
understanding of genes, molecular and cell biology studies. On the other hand, attention in
these viruses extends beyond their disease causing capabilities, discovery of oncogenes,
understanding of mechanisms that regulate eukaryotic gene expression was possible because
of the study on retroviruses. The complete understanding of retrovirus could help the
researchers and clinicians to use them in various fields of biology and medicine for the
development of new methodologies and techniques. Ongoing investigation on application of
retroviruses in gene therapy and anti-cancer agents makes these type a widely studying group.
The way retroviruses enter and target the specific cells and integrate itself into the host genome
was very fascinating to the scientists globally, and these can be used as models to develop new
vectors that could be employed in research. Collaborative international project needs to be
taken up to understand the complete life cycle of retroviruses. The reason is that this not only
aids in developing antiviral, but also gives us idea where gained knowledge could be applied
in other fields such as engineering and material sciences and to develop new technologies.
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